Healthcare Stocks Poised for Growth Under Obamacare: MYL, ESRX, AMGN, CELG, REGN, JNJ, NVO, BAX, MWIV

By Robert Freedland

Healthcare - stocks - sector2012 was a very good year for the Covestor Healthcare model that I manage. I attribute the strong performance to the healthcare sector, which turned out to be a good area for the average investor.

With the Affordable Care Act (“Obamacare”) continuing to roll out into 2013, I believe that the added patient volume that should come along with the expanded coverage will bring opportunity as well as stress to the healthcare community.

Companies that help reduce costs and improve efficiencies for healthcare delivery should benefit. These companies include stocks involved in providing less expensive drugs whether by utilizing generics including drugs produced by Mylan Inc. (NASDAQ:MYL), a significant holding in the model, or by cost-effective delivery by a company like Express Scripts Holding Company (NASDAQ:ESRX) a stock that I have owned in the past, but do not currently hold.

The future remains bright for biotech companies that are producing real products treating real diseases. These include Healthcare Model holdings Amgen Inc. (NASDAQ:AMGN), Celgene (NASDAQ:CELG), and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).

The added patient volume associated with healthcare reform will contribute to revenue growth at established large pharmaceutical and healthcare supply companies like Johnson & Johnson (NYSE:JNJ), Novo Nordisk (NYSE:NVO) and Baxter International Inc. (NYSE:BAX), all three are holdings of the Healthcare Model.

One area that I have included in the Model involves healthcare for animals with MWI Veterinary Supply Inc. (NASDAQ:MWIV). This company delivers supplies to veterinarians and is growing quickly and should have potential to continue to grow into 2013.

In my opinion, this sector will continue to be strong into 2013. I will continue to ‘ride herd’ over this group of stocks and be quick to exit any holding with any fundamental negative announcement or actual technical price weakness that might suggest price decline into the future. However, I shall work to be patient with those holdings that are doing well and continue to look for new possibilities and ideas for inclusion into the New Year.

The above article comes from Covestor. For more information on RobertFreedlandand to view his Buy and Hold Value Covestor Model, visit Covestor.com

Covestor Ltd. is a registered investment advisor. Covestor licenses investment strategies from its Model Managers to establish investment models. The commentary here is provided as general and impersonal information and should not be construed as recommendations or advice. Information from Model Managers and third-party sources deemed to be reliable but not guaranteed. Past performance is no guarantee of future results. Transaction histories for Covestor models available upon request. Additional important disclosures available at http://site.covestor.com/help/disclosures. For information about Covestor and its services, go to http://covestor.com or contact Covestor Client Services at (866) 825-3005, x703.


Comments are closed.